Patents by Inventor Venkatraman Mohan

Venkatraman Mohan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6541456
    Abstract: The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention comprises at least one aryl, heteroaryl, substituted aryl or substituted heteroaryl group in place of a glycosyl group attached to the 2-deoxystreptamine ring.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: April 1, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric Swayze, Richard H. Griffey, Yili Ding, Venkatraman Mohan
  • Patent number: 6534639
    Abstract: The present invention provides oligomers which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the nucleoside moieties of the oligomer is modified to include a guanidinium group. These oligomers are useful for diagnostic, therapeutic and investigative purposes.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: March 18, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Phillip Dan Cook, Thazha P. Prakash, Venkatraman Mohan
  • Publication number: 20030017483
    Abstract: Methods for the identification of compounds which modulate, either inhibit or stimulate, biomolecules are provided. Nucleic acids, especially RNAs are preferred substrates for such modulation. The present methods are particularly powerful in that they provide novel combinations of techniques which give rise to compounds, usually “small” organic compounds, which are highly potent modulators of RNA and other biomolecular activity. In accordance with preferred aspects of the invention, very large numbers of compounds may be tested essentially simultaneously to determine whether they are likely to interact with a molecular interaction site and modulate the activity of the biomolecule. Pharmaceuticals, veterinary drugs, agricultural chemicals, industrial chemicals, research chemicals and many other beneficial compounds may be identified in accordance with embodiments of this invention.
    Type: Application
    Filed: March 22, 2002
    Publication date: January 23, 2003
    Inventors: David J. Ecker, Richard Griffey, Stanley T. Crooke, Ranga Sampath, Eric Swayze, Venkatraman Mohan, Steven Hofstadler
  • Publication number: 20020052526
    Abstract: The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention comprises at least one aryl, heteroaryl, substituted aryl or substituted heteroaryl group in place of a glycosyl group attached to the 2-deoxystreptamine ring.
    Type: Application
    Filed: November 30, 2000
    Publication date: May 2, 2002
    Inventors: Eric Swayze, Richard H. Griffey, Yili Ding, Venkatraman Mohan
  • Patent number: 6369209
    Abstract: Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-form geometry imparts properties to the oligonucleotide that modulate binding affinity and nuclease resistance. By utilizing C2′ endo sugars or O4′ endo sugars, the B-form characteristics are imparted to a portion of the oligonucleotide. The A-form characteristics are imparted via use of either 2′-O-modified nucleotides that have 3′ endo geometries or use of end caps having particular nuclease stability or by use of both of these in conjunction with each other.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: April 9, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Venkatraman Mohan
  • Patent number: 6271358
    Abstract: 2′-O-modified ribosyl nucleosides and modified oligonucleotides containing such nucleotides are disclosed. Oligonucleotides are disclosed that have increased binding affinity as shown by molecular modeling experiments. The 2′-O-modified nucleosides of the invention include ring structures that position the sugar moiety of the nucleosides preferentially in 3′ endo geometries.
    Type: Grant
    Filed: July 27, 1998
    Date of Patent: August 7, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Venkatraman Mohan, Herb Boswell
  • Patent number: 6084082
    Abstract: Novel .beta.-lactam monomers bearing various functional groups are prepared. The novel .beta.-lactam monomers can be joined into oligomeric compounds such as via preferred phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen bonding. The oligomeric compounds are useful as diagnostic and research reagents.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: July 4, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Vasulinga Ravikumar, Venkatraman Mohan
  • Patent number: 5866691
    Abstract: Novel .beta.-lactam monomers bearing various functional groups are prepared. The novel .beta.-lactam monomers can be joined into oligomeric compounds such as via preferred phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen bonding. The oligomeric compounds are useful as diagnostic and research reagents.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: February 2, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Vasulinga Ravikumar, Venkatraman Mohan
  • Patent number: 5554746
    Abstract: Novel .beta.-lactam monomers bearing various functional groups are prepared. The novel .beta.-lactam monomers can be joined into oligomeric compounds such as via preferred phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen bonding. The oligomeric compounds are useful as diagnostic and research reagents.
    Type: Grant
    Filed: May 16, 1994
    Date of Patent: September 10, 1996
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Vasulinga Ravikumar, Venkatraman Mohan